In general, in vivo models of T2D, obesity, and hypertension have shown that probiotics can assist in insulin sensitization, regulate glucose transporters (GLUT4) and incretins (GLP-1), reduce LPS and proinflammatory cytokines, and maintain intestinal barrier integrity. The gene discussed is GCG; the disease is Obesity.